EBNA-1 Protein (562-570) FMVFLQTHI
Vorteile im Überblick
- Hochwertige Produkte
- Kundenspezifische Lösungen
- Persönlicher Kontakt
- Schneller Service
- Kompetenter technischer Support +49(0)731-3608-123
| Anzahl | Stückpreis |
|---|---|
| Bis 2 |
215,75 €*
|
| Ab 3 |
161,81 €*
215,75 €*
(25% gespart)
|
Lieferzeit: 3 - 8 Werktage
Für genaue Informationen zum Liefertermin wenden Sie sich bitte an Genaxxon.
Shipment: not cooled. Store at -20°C. For laboratory usage only!
The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalo virus).
On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cell as EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions.
A very limited, distinct set of viral proteins are produced during latent cycle infection. These include Epstein-Barr nuclear antigen (EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-leader protein (EBNA-LP) and latent membrane proteins (LMP)-1, LMP-2A and LMP-2B and the Epstein-Barr encoded RNAs (EBERs).
Specifications:
Purity: >95% (HPLC)
Sequence: FMVFLQTHI
Lyophilized powder
Sicherheits Hinweise / Safety
Klassifizierungen / Classification
eclass-Nr: 32-16-04-09
Dokumente:
Allg. Daten 1Allg. Daten 2
Kategorienliste
Quelle: NCBI PubMed
Hier finden Sie Artikel und Literaturzitate, in denen die Autoren auf die hohe Qualität dieses Genaxxonprodukts vertrauen.
Listed below are articles and references, in which the authors trust in the high quality of this Genaxxon product.
Quelle/Source: NCBI PubMed >
TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation
Dominik Wieland, Janine Kemming, Anita Schuch, Florian Emmerich, Percy Knolle, Christoph Neumann-Haefelin, Werner Held, Dietmar Zehn, Maike Hofmann, Robert Thimme
Nat Commun. 2017; 8: 15050. Published online 2017 May 3. doi: 10.1038/ncomms15050
PMCID: PMC5418623